710 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by New England Research & Management Inc.

New England Research & Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,185 shares of the biopharmaceutical company’s stock after purchasing an additional 710 shares during the period. Regeneron Pharmaceuticals makes up about 1.2% of New England Research & Management Inc.’s investment portfolio, making the stock its 23rd biggest position. New England Research & Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $5,682,636,000. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares during the last quarter. Invesco Ltd. increased its position in Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after purchasing an additional 106,632 shares during the period. Bank of America Corp DE increased its position in Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares during the period. Finally, Amundi increased its position in Regeneron Pharmaceuticals by 27.5% in the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after purchasing an additional 217,892 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. HSBC lifted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target for the company in a research note on Thursday, October 1st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Finally, BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $845.21.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.7%

NASDAQ:REGN traded down $5.60 during mid-day trading on Friday, hitting $790.74. The company had a trading volume of 653,510 shares, compared to its average volume of 800,313. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $566.11 and a fifty-two week high of $859.34. The firm has a market cap of $81.41 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.38 and a beta of 0.16. The business’s fifty day moving average is $791.72 and its two-hundred day moving average is $721.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.